Posters

Choroidal thickness as a prognostic factor for response to ranibizumab therapy in diabetic macular edema

Poster Details

First Author: S.Erdenöz TURKEY

Co Author(s):    D. Zincirci   B. Erden   S. Ocak   M. Elcioglu                    

Abstract Details



Purpose:

To evaluate the correlation between baseline subfoveal choroidal thickness (SCT) and central macular thickness after administration of three monthly loading doses of intravitreal ranibizumab (RAN) treatment in patients with diabetic macular edema (DME), using spectral domain optical coherence tomography (SD-OCT) imaging.

Setting:

Okmeydani education and research hospital/ Istanbul

Methods:

Seventy-nine eyes of 61 patients with diabetic macular edema were treated with three monthly loading doses of intravitreal injection of RAN. Central macular thickness (CMT) was compared between values obtained at baseline and after loading dosage of RAN, and researched the correlation with baseline subfoveal choroidal thickness.

Results:

Seventy-nine eyes of 61 patients (29 females, 32 males) were enrolled (mean age, 62.71 ± 7.5 years; range, 40-77 years). Patients were divided into two groups by SCT: Patients with SCT is equal or greater than 270 µm is divided in group one (GR1), and thinner than 270 µm in group two (GR2). Comparing the pretreatment and final values, the CMT reduction was significant (394,53 µm and 301.86 µm respectively) in both groups (P<0.01). CMT reduction was significantly greaterin the GR1 (128,70 µm) than in the GR2 (60.93 µm), it was significantly different (P<0.01).

Conclusions:

The choroid is involved in the pathology of DME. The SCT at the baseline may be a predictive factor in the treatment of intravitreal injection of ranibizumab for macular edema secondary to diabetes mellitus.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy